Byondis
Marieke van Gent has extensive experience in intellectual property, holding various director positions in companies such as Byondis, Nouryon, AkzoNobel Specialty Chemicals, and FrieslandCampina. With a background in patent law, Marieke has played key roles in managing patent matters, leading IP teams, and being a member of global IP management teams. Their expertise in IP has been a valuable asset in their career, making their a seasoned professional in the field.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.